 "European drug regulator approvals Biocon's first generic formulation")
The Bengaluru-based biopharmaceuticals company Biocon Ltd yesterday announced that it has received approval from the European Directorate for the Quality of Medicines
(EDQM) for its rosuvastatin calcium tablets (5 mg, 10 mg, 20 mg and 40 mg), a generic equivalent of AstraZeneca’s Crestor
This first generic formulations approval in the regulated markets marks an important milestone in Biocon’s small molecules strategy of forward integration from APIs to finished dosages.
Kiran Mazumdar-Shaw, chairperson & managing director, Biocon, said, “This is indeed a proud moment for Biocon’s small molecules business. This approval paves the way for Biocon to launch rosuvastatin calcium tablets in several European countries. We plan to collaborate with regional partners in the near term to provide access to this affordable generic and thus help patients and governments to bring down their healthcare spends.”
The approval for rosuvastatin calcium, indicated for hyperlipidemia or mixed dyslipidemia, will open the doors for Biocon to over 15 European countries and will enable the company to address $ 1.2 billion opportunity, starting FY17.
Biocon was the first generic company to receive a Certificate of Suitability (CEP) for rosuvastatin calcium API from the EDQM. CEP certification indicates that an API is suitable for use in medicinal products in the EU.
Dr Arun Chandavarkar, CEO and joint managing director, Biocon, added, “The European approval for Biocon’s generic version of rosuvastatin calcium underscores Biocon’s unique strengths in the chronic therapies space and our compliance with global standards that enable us to achieve the highest quality standards for all our products. It augurs well for this nascent business, which will be one of our growth drivers in the coming years.”
Biocon aims to rev up its generic formulations business with a target of 20-25 filings over the next few years. Its new potent oral solid dosage formulations facility coming up in Bengaluru will enable this business expansion. The company is also working on dossiers to introduce these formulations in emerging markets where regulatory clearances are primarily based on approvals given by regulators in the US/EU.
(EDQM) for its rosuvastatin calcium tablets (5 mg, 10 mg, 20 mg and 40 mg), a generic equivalent of AstraZeneca’s Crestor
This first generic formulations approval in the regulated markets marks an important milestone in Biocon’s small molecules strategy of forward integration from APIs to finished dosages.
Kiran Mazumdar-Shaw, chairperson & managing director, Biocon, said, “This is indeed a proud moment for Biocon’s small molecules business. This approval paves the way for Biocon to launch rosuvastatin calcium tablets in several European countries. We plan to collaborate with regional partners in the near term to provide access to this affordable generic and thus help patients and governments to bring down their healthcare spends.”
The approval for rosuvastatin calcium, indicated for hyperlipidemia or mixed dyslipidemia, will open the doors for Biocon to over 15 European countries and will enable the company to address $ 1.2 billion opportunity, starting FY17.
Biocon was the first generic company to receive a Certificate of Suitability (CEP) for rosuvastatin calcium API from the EDQM. CEP certification indicates that an API is suitable for use in medicinal products in the EU.
Dr Arun Chandavarkar, CEO and joint managing director, Biocon, added, “The European approval for Biocon’s generic version of rosuvastatin calcium underscores Biocon’s unique strengths in the chronic therapies space and our compliance with global standards that enable us to achieve the highest quality standards for all our products. It augurs well for this nascent business, which will be one of our growth drivers in the coming years.”
Biocon aims to rev up its generic formulations business with a target of 20-25 filings over the next few years. Its new potent oral solid dosage formulations facility coming up in Bengaluru will enable this business expansion. The company is also working on dossiers to introduce these formulations in emerging markets where regulatory clearances are primarily based on approvals given by regulators in the US/EU.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%